恩格列净在合并心血管疾病的2型糖尿病女性中的应用:EMPA-REG OUTCOME®分析
EMPA-REG OUTCOME®试验的二次分析,共纳入2004例女性和5016例男性2型糖尿病合并动脉粥样硬化性心血管疾病患者,随机接受恩格列净10mg、25mg或安慰剂每日一次。在统计效力限制内,未检测到恩格列净对心血管死亡、心衰住院及新发或恶化肾病的疗效存在性别差异(交互作用P值分别为0.32、0.20、0.85)。恩格列净在女性和男性中均增加生殖道感染率。
要点
- 恩格列净降低心血管死亡、心衰住院和新发或恶化肾病的效应在女性和男性间无差异。
- 女性基线LDL-C数值更高(2.5±1.0 vs 2.1±0.9 mmol/l),降脂治疗率更低(75.4% vs 83.2%)。
- 恩格列净增加生殖道感染率:女性2.5% vs 10.0%,男性1.5% vs 2.6%。
核心结论
- 恩格列净诱导的心血管死亡、心衰住院及新发或恶化肾病发生率降低在女性和男性之间无差异。
研究设计与样本
- EMPA-REG OUTCOME®试验的二次分析,纳入2004例女性和5016例男性2型糖尿病合并动脉粥样硬化性心血管疾病患者,随机接受恩格列净10mg、25mg或安慰剂每日一次,随访至至少691例个体发生主要结局的裁定事件。
主要发现
- 女性安慰剂组年化发生率:心血管死亡1.58% vs 男性2.19%,心衰住院1.75% vs 1.33%,肾脏事件7.22% vs 7.75%。
- 恩格列净对心血管死亡、心衰住院及新发或恶化肾病的效应无性别交互作用(交互作用P值分别为0.32、0.20、0.85)。
- 与安慰剂相比,恩格列净增加生殖道感染率:女性2.5% vs 10.0%,男性1.5% vs 2.6%。
局限性
- 分析受统计效力限制,未检测到性别效应修饰。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The global epidemic of type 2 diabetes affects women and men equally; however, the relative impact on the cardiovascular (CV) system appears greater for women than men when compared with peers without diabetes. Furthermore, women are often under-represented in CV outcome trials, resulting in less certainty about the impact of CV prevention therapies across the sexes. The EMPA-REG OUTCOME® trial, which included 28.5% women, found that empagliflozin, given in addition to standard of care, reduced the risk of CV death by 38%, heart failure (HF) hospitalisation by 35% and a composite endpoint for incident or worsening nephropathy by 39%. Here we report a secondary analysis of the trial to determine the relative effects of empagliflozin in women vs men. METHODS: The population studied were individuals with type 2 diabetes (HbA1c 53-86 mmol/mol [7-10%] and eGFR >30 ml min-1 [1.73 m]-2), with established atherosclerotic CV disease. Individuals were randomised to receive empagliflozin 10 mg or 25 mg, or placebo once daily in addition to standard of care, and followed. The trial continued until ≥691 individuals had experienced an adjudicated event included in the primary outcome. All CV outcome events, including HF hospitalisations and deaths were prospectively adjudicated by blinded clinical events committees. RESULTS: At baseline, the demographic profile of the 2004 women (age ± standard deviation 63.6 ± 8.8 years) compared with the 5016 men (age 63.0 ± 8.6 years) in the trial was largely similar, with the exception that LDL-cholesterol was numerically higher in women (2.5 ± 1.0 vs 2.1 ± 0.9 mmol/l), consistent with lower rates of lipid-lowering therapies (75.4% vs 83.2%). Women were also less likely to have smoked (31.5% vs 69.9%). The annualised incidence rate for women in the placebo group was numerically lower than in men for CV death (1.58% vs 2.19%), numerically higher for HF hospitalisation (1.75% vs 1.33%) and similar for renal events (7.22% vs 7.75%). We did not detect any effect modification by sex within the statistical power restrictions of the analysis for CV death, HF hospitalisation and incident or worsening nephropathy (interaction p values 0.32, 0.20 and 0.85, respectively). Compared with placebo, empagliflozin increased the rates of genital infections in both women (2.5% vs 10.0%) and men (1.5% vs 2.6%). CONCLUSIONS/INTERPRETATION: CV death, HF hospitalisation and incident or worsening nephropathy rate reductions induced by empagliflozin were not different between women and men.
引用
- Zinman B, Inzucchi SE, Wanner C, et al. Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®. Diabetologia. 2018. PMID: 29713728. doi:10.1007/s00125-018-4630-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。